Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.96 (market cap $29.60B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5. The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BIL | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $91.77 |
52-Week Low | $205.48 | $91.27 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
BIL, the SPDR Bloomberg 1-3 Month T-Bill ETF, trades at $91.50, up 0.02% on the day, with a bearish technical signal from moving averages. The fund provides exposure to short-term U.S. Treasury bills, with recent institutional buying activity noted. Key support and resistance cluster around $91, while the relative strength index at 21.69 indicates potential oversold conditions.
The outlook for BIL is influenced by Federal Reserve policy expectations and Treasury yield movements. Rising yields may pressure returns, but the fund offers a low-risk cash alternative. Risks include interest rate volatility and inflation data surprises, with investor sentiment cautious amid geopolitical tensions affecting oil prices and bond markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
